Company intelligence / Profile preview

Claradele Pharmaceuticals

Ownership: Private
Development stage: Preclinical

Overview

Their lead compound 15dPMJ2 has shown promising results in preclinical trials, reducing tumor growth by 76% and increasing tumor infiltration of immune cells that attack cancer. The compound demonstrates tumor selectivity by inducing cytotoxic endoplasmic reticulum stress.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

15dPMJ2

Pre-clinical

Indications: Melanoma, Colon cancer, Lung cancer, Actinic keratosis

Partnerships

Consortium of academic scientists

Beyond the preview

Go deeper on Claradele Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Claradele Pharmaceuticals.

Explore the full profile